CLINICAL TRIALS PROFILE FOR ZILEUTON
✉ Email this page to a colleague
All Clinical Trials for zileuton
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00056004 ↗ | Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia | Completed | National Cancer Institute (NCI) | Phase 2 | 2003-06-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of zileuton may be an effective way to prevent lung cancer in patients who have bronchial dysplasia. PURPOSE: Randomized phase II trial to study the effectiveness of zileuton in preventing lung cancer in patients who have bronchial dysplasia. |
| NCT00056004 ↗ | Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia | Completed | Barbara Ann Karmanos Cancer Institute | Phase 2 | 2003-06-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of zileuton may be an effective way to prevent lung cancer in patients who have bronchial dysplasia. PURPOSE: Randomized phase II trial to study the effectiveness of zileuton in preventing lung cancer in patients who have bronchial dysplasia. |
| NCT00070486 ↗ | Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2003-12-01 | RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib and zileuton may stop the growth of tumor cells by stopping blood flow to the tumor and may block the enzymes necessary for tumor cell growth. Combining chemotherapy with celecoxib and/or zileuton may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combining celecoxib and/or zileuton with carboplatin and gemcitabine in treating patients who have advanced non-small cell lung cancer. |
| NCT00070486 ↗ | Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer | Completed | Alliance for Clinical Trials in Oncology | Phase 2 | 2003-12-01 | RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib and zileuton may stop the growth of tumor cells by stopping blood flow to the tumor and may block the enzymes necessary for tumor cell growth. Combining chemotherapy with celecoxib and/or zileuton may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combining celecoxib and/or zileuton with carboplatin and gemcitabine in treating patients who have advanced non-small cell lung cancer. |
| NCT00098358 ↗ | Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris | Unknown status | Critical Therapeutics | Phase 2 | 2004-11-01 | Tissue inflammation is a major component of the acne disease process. Leukotriene B4 (LTB4) is thought to be a major player in the development of tissue inflammation. Synthesis of LTB4 is controlled by the enzyme 5-lipoxygenase. Zileuton blocks the activity of 5-lipoxygenase. This study will test the safety and efficacy of zileuton in the treatment of facial acne. |
| NCT00262405 ↗ | Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis | Completed | National Institutes of Health (NIH) | Phase 2 | 2001-01-01 | Open label trial of zileuton compared to azathioprine/prednisone for patients with idiopathic pulmonary fibrosis. Study subjects will undergo a detailed clinical, radiographic, and physiologic assessment at baseline. Subjects will be monitored off treatment for three months for changes in symptoms and physiology. Subjects will then be randomized to six months of treatment with zileuton or azathioprine/prednisone. The primary endpoint of this trial is change in LTB4 levels in bronchoalveolar lavage fluid following six months of treatment. Secondary endpoints are progression free survival, change in dyspnea, change in quality of life, and change in physiology. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for zileuton
Condition Name
Clinical Trial Locations for zileuton
Trials by Country
Clinical Trial Progress for zileuton
Clinical Trial Phase
Clinical Trial Sponsors for zileuton
Sponsor Name
